ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting

    Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death

    Ana Beatriz Vargas-Santos1, Tuhina Neogi2, Geraldo Castelar-Pinheiro1 and Aleksandra Turkiewicz3, 1Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, 2Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 3Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden

    Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…
  • Abstract Number: 2847 • 2017 ACR/ARHP Annual Meeting

    The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout

    Abhishek Abhishek1, Wendy Jenkins1, Philip Courtney2, Adrian Jones3, Weiya Zhang4 and Michael Doherty5, 1Devision of Rheumatology, University of Nottingham, NG5 1PB, England, 2Department of Rheumatology, Notingham, United Kingdom, 3Rheumatology Unit, Nottingham City Hospital, Nottingham Notts, United Kingdom, 4Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham, United Kingdom, 5Academic Rheumatology, University of Nottingham, Nottingham, Great Britain

    Background/Purpose: Hyperuricemia and gout aggregate in families. The objectives of this study were to estimate the prevalence of asymptomatic monosodium urate (MSU) crystal deposition in…
  • Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting

    Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study

    Ted R. Mikuls1, TC Cheetham2, Gerald D. Levy3, Nazia Rashid4, Kimberly Low5, Brian W Coburn6, Kenneth Saag7, Lang Chen8 and Jeffrey R. Curtis9, 1Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 3Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, 4Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, 5Kaiser Permanente Southern California, Panorama City, CA, 6Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of Alabama at Birmingham, Birmingham, AL, 9Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:   Allopurinol is a cornerstone therapy in gout management.  Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
  • Abstract Number: 2849 • 2017 ACR/ARHP Annual Meeting

    Pain and Functional Trajectories in Symptomatic Knee Osteoarthritis over a 12-Week Period of Non-Pharmacological Exercise Interventions

    Augustine Lee1, William F. Harvey2, Xingyi Han1, Lori Lyn Price3,4, Jeffrey B. Driban1, Raveendhara R. Bannuru1 and Chenchen Wang2, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, 3Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, 4Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA

    Background/Purpose: Exercise is the recommended treatment for knee osteoarthritis (OA). However, heterogeneous patterns in treatment response are poorly understood. Our purpose was to identify pain…
  • Abstract Number: 2850 • 2017 ACR/ARHP Annual Meeting

    Jakinibs Decrease Chronic Low Back Pain and Increase Function: A Proof of Concept Trial

    Maria Greenwald1 and JoAnn Ball2, 1Desert Medical Advances, Palm Desert, CA, 2rheumatology, Desert Medical Advances, Palm Deseret, CA

    Background/Purpose: Low back pain (LBP) is ubiquitous and estimated to affect 26% of Americans in any 3 month period. Why would rheumatoid arthritis patients be…
  • Abstract Number: 2851 • 2017 ACR/ARHP Annual Meeting

    General and Abdominal Obesity As Risk Factors for Late-Life Mobility Limitation Among Women with Total Knee or Hip Replacement for Osteoarthritis

    Aladdin Shadyab1, Wenjun Li2, Charles Eaton3 and Andrea LaCroix4, 1Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, 2Medicine, University of Massachusetts Medical School, Worcester, MA, 3Family Medicine and Epidemiology, Warren Alpert Medical School, School of Public Health, Brown University, Providence, RI, 4Family Medicine and Public Health, University of California, San Diego School of Medicine, La Jolla, CA

    Background/Purpose: The population is rapidly aging, and by 2060, more than 12 million women will be ages 85 years and older in the United States.…
  • Abstract Number: 2852 • 2017 ACR/ARHP Annual Meeting

    Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women

    Ernest Vina1, Di Ran2, Erin L. Ashbeck2 and C. Kent Kwoh3, 1Rheumatology, University of Arizona, Tucson, AZ, 2The University of Arizona Arthritis Center, Tucson, AZ, 3University of Arizona, Tucson, AZ

    Background/Purpose: Up to 47% of individuals may not have clinically significant improvement following joint replacement surgery. Evidence also suggests that women are less likely to…
  • Abstract Number: 2853 • 2017 ACR/ARHP Annual Meeting

    Is Frailty Associated with Adverse Events after Total Joint Arthroplasty?

    Lisa A. Mandl1,2, Abigail M. Schmucker3, Nathaniel Hupert4, Mayu Sasaki3, Charles N. Cornell5,6, Michael B. Cross5,6, Alejandro Gonzalez Della Valle5,6, Mark P. Figgie6,7, Seth A. Jerabek5,6, Jackie Szymonifka1 and Steven K. Magid8,9, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Medicine - Rheumatology, Weill Cornell Medicine, New York, NY, 3Quality Research Center, Hospital for Special Surgery, New York, NY, 4Medicine, Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, 5Surgery, Hospital for Special Surgery, New York, NY, 6Surgery, Weill Cornell Medicine, New York, NY, 7Orthopaedics, Hospital for Special Surgery, New York, NY, 8Medicine - Rhuematology, Hospital for Special Surgery, New York, NY, 9Medicine, Weill Cornell Medicine, New York, NY

    Background/Purpose: The increased volume of TJA due to the aging population requires a better understanding of the effect of physiological frailty, in addition to chronological…
  • Abstract Number: 2854 • 2017 ACR/ARHP Annual Meeting

    Optimizing Data Capture for Performance – Metrics Using Smartphone App Technology

    James Willig1, Jeffrey R. Curtis2, Andrew Westfall3, Donald Lein4, Christian Ray Smith4, Jonathan Cortis5, Clayton Rice5 and Christopher Hurt4, 1Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham, Birmingham, AL, 5CTS, Inc, Birmingham, AL

    Background/Purpose: Gait speed has been associated with many clinical outcomes (e.g. frailty, mortality, joint replacement need, etc.) relevant for rheumatologic conditions. Measuring Gait speed (stride…
  • Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting

    Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years

    Hermine I. Brunner1, N Ruperto2, G Vega-Cornejo3, A Berman4, Inmaculada Calvo5, R Cuttica6, F Ávila-Zapata7, Michael Henrickson1, DJ Kingsbury8, D Viola9, V Keltsev10, K Minden11, John F. Bohnsack12, X Li13, M Nys14, R Wong13, S Banerjee13, Daniel J Lovell1 and Alberto Martini15, 1Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, 2Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, 3Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, 4Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, 5Hospital Univ. La Fe, Valencia, Spain, 6Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 7Star Medica Hospital, Yucatán, Mexico, 8Randall Children’s Hospital at Legacy Emanuel, Portland, OR, 9CAICI Institute, Rosario City, Santa Fe State, Argentina, 10GBUZ Samara region "Togliatti City Clinical Hospital No.5" Rheumatology Department, Togliatti, Russian Federation, 11German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, 12University of Utah School of Medicine, Salt Lake City, UT, 13Bristol-Myers Squibb, Princeton, NJ, 14Bristol-Myers Squibb, Braine-l’Alleud, Belgium, 15Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy

    Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…
  • Abstract Number: 2856 • 2017 ACR/ARHP Annual Meeting

    Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis

    Navita L. Mallalieu1, Joy Hsu1, Karen Wang1, Sunethra Wimalasundera2, Wendy Douglass2, Chris Wells2, Inmaculada Calvo3, Rubén Cuttica4, Hans-Iko Huppertz5, Rik Joos6, Yukiko Kimura7, Diana Milojevic8, Margalit Rosenkranz9, Kenneth Schikler10, Tamas Constantin11 and Carine Wouters12, 1Roche Innovation Center, New York, NY, 2Roche Products, Ltd., Welwyn Garden City, United Kingdom, 3Hospital Universitario y Politécnico La Fe, Valencia, Spain, 4Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, 5Professor Hess Children's Hospital, Bremen, Germany, 6ZNA, Antwerp, and UZ, Gent, Belgium, 7Hackensack University Medical Center, Hackensack, NJ, 8Tufts Medical Center, Boston, MA, 9Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 10University of Louisville Medical School, Louisville, KY, 11Semmelweis University, Budapest, Hungary, 12University Hospital Gasthuisberg, Leuven, Belgium

    Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…
  • Abstract Number: 2857 • 2017 ACR/ARHP Annual Meeting

    Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis

    Nuria Vegas-Revenga1, Vanesa Calvo-Río1, Montserrat Santos-Gómez2, Inmaculada Calvo3, Mº Isabel González- Fernández3, Berta López- Montesinos3, Marina Mesquida4, Alfredo Adan4, M. Victoria Hernández4, Olga Maiz5, Antonio Atanes6, Beatriz Bravo7, Consuelo Modesto8, Gisela Díaz-Cordovés9, Natalia Palmou-Fontana1, Javier Loricera1, MC Gonzalez-Vela10, Rosalia Demetrio11, Carlos Fernández-Díaz1, Lucia C. Domínguez-Casas1, José Luis Martín-Varillas1, Belén Atienza-Mateo1, Jose L. Hernández12, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 3Rheumatology, Hospital Universitario i Politecnico La Fe. Valencia. Spain, Valencia, Spain, 4Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Hospital Donostia. Spain, San Sebastian, Spain, 6Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, 7Rheumatology, HU Virgen de las Nieves. Granada. Spain, Granada, Spain, 8Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, 9Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, 10Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 11Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 12Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Our objective was to assess the efficacy of tocilizumab (TCZ) at short and long term follow-up for severe juvenile idiopathic arthritis-associated uveitis.Methods: A Multicentre…
  • Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting

    Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy

    Daniel J Lovell1, Sarah Ringold2 and P. Scott Eastman3, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Seattle Children's Hospital, Seattle, WA, 3Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA

    Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
  • Abstract Number: 2859 • 2017 ACR/ARHP Annual Meeting

    Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis

    Alessandro Consolaro1,2, Pieter Van Dijkhuizen1, Graciela Espada3, Boriana Varbanova4, Sheila Oliveira5, Paivi Miettunen4, Gaëlle Chédeville5, Michaël Hofer5, Pavla Dolezalová5, Ivan Foeldvari5, Gerd Horneff5, Anne Estmann5, Chris Pruunsild5, Rosa Merino5, Inmaculada Calvo Penades5, Pablo Mesa del Castillo5, Pekka Lahdenne5, Maka Ioseliani5, Maria Trachana5, Olga Vougiouka5, Miroslav Harjacek5, Ilonka Orban5, Tamás Constantin5, Nahid Shafaie5, Violeta Vladislava Panaviene5, Marite Rygg5, Elzbieta Smolewska5, Jose Antonio Melo Gomes5, Jelena Vojinovic5, Ekaterina Alexeeva5, Tadej Avcin5, Veronika Vargova5, Nuray Aktay Ayaz6, Ozgur Kasapcopur5, Yaryna Boyko5, Sarah Ringold5, Mariangela Rinaldi5, Marco Garrone5, Nicolino Ruperto7 and Angelo Ravelli8,9, 1Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, 2University of Genova, GENOA, Italy, 3Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, 4Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, GENOA, Italy, 5Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, 6Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Gernoa, Italy, 7Istituto Giannina Gaslini, Genoa, Italy, 8University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, 9University of Genova, Genova, Italy

    Background/Purpose: The measurement of the level of disease activity plays a pivotal role in the care of patients with ju­venile idiopathic arthritis (JIA). To serve…
  • Abstract Number: 2860 • 2017 ACR/ARHP Annual Meeting

    Enthesitis-Related Arthritis: Axial -Pattern  Is Associated with an Expansion of Peripheral Th17 Populations .

    Maria M. Katsicas1, Carolina Carrara2 and Ricardo Russo3, 1Service of Immunology & Rheumatology., Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, 2Immunology& Rheumatology, Hospital de Pediatría Prof Dr JP Garrahan, Buenos Aires, Argentina, 3Service of Immunology/Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina

    Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis encompassing most cases of juvenile spondyloarthropathy. Two different clinical patterns (axial /peripheral) have been…
  • « Previous Page
  • 1
  • …
  • 1575
  • 1576
  • 1577
  • 1578
  • 1579
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology